Replies to post #147500 on Biotech Values

[jq1234]

Nonetheless, given the purported magnitude of the benefit in the second line trial, one would expect to see at least a hint of benefit in the front-line trial if the signal is "real".

I agree completely. It is always possible, but unlikely IMO. 1st line is with carboplatin and paclitaxel. Docetaxel is semi-sythetic analogue of paclitaxel, shouldn't make dramatic difference. There was no difference in PFS in 1st line, not even numerical one like in 2nd line.

[geocappy1]

Why don't we just wait for the results. You are correct in pointing out that 2nd line uses Doce as a chemo agent which is different than the chemo agent used in the front line trial. Dr. Thorpe pointed out a while back that Doce seemed to expose the PS on the cells to a greater extent making it a better target for bavi. Also, in a prior signal seeking trial using Doce and Bavi on metastisized Breast cancer there were very good results so yes it appears Doce is the better combo. However, for those who are interested in science and not necessarily disproving Bavi and PPHM, the use of Bavi with radiation may be better yet do to the fact that the PS is even more exposed.